SOPHIA GENETICS SA (SOPH) Fundamental Analysis & Valuation

NASDAQ:SOPH • CH1125843347

Current stock price

4.85 USD
-0.02 (-0.41%)
At close:
4.85 USD
0 (0%)
After Hours:

This SOPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SOPH Profitability Analysis

1.1 Basic Checks

  • In the past year SOPH has reported negative net income.
  • SOPH had a negative operating cash flow in the past year.
  • SOPH had negative earnings in each of the past 5 years.
  • SOPH had a negative operating cash flow in each of the past 5 years.
SOPH Yearly Net Income VS EBIT VS OCF VS FCFSOPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • SOPH has a worse Return On Assets (-48.46%) than 77.14% of its industry peers.
  • With a Return On Equity value of -167.57%, SOPH is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -48.46%
ROE -167.57%
ROIC N/A
ROA(3y)-42.34%
ROA(5y)-37.18%
ROE(3y)-94.83%
ROE(5y)-70.99%
ROIC(3y)N/A
ROIC(5y)N/A
SOPH Yearly ROA, ROE, ROICSOPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • SOPH's Gross Margin of 67.40% is fine compared to the rest of the industry. SOPH outperforms 62.86% of its industry peers.
  • SOPH's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SOPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.85%
GM growth 5Y1.59%
SOPH Yearly Profit, Operating, Gross MarginsSOPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. SOPH Health Analysis

2.1 Basic Checks

  • SOPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SOPH has more shares outstanding than it did 1 year ago.
  • SOPH has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SOPH is higher compared to a year ago.
SOPH Yearly Shares OutstandingSOPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
SOPH Yearly Total Debt VS Total AssetsSOPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • SOPH has an Altman-Z score of -2.42. This is a bad value and indicates that SOPH is not financially healthy and even has some risk of bankruptcy.
  • SOPH has a Altman-Z score of -2.42. This is in the lower half of the industry: SOPH underperforms 65.71% of its industry peers.
  • SOPH has a Debt/Equity ratio of 1.28. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of SOPH (1.28) is worse than 88.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF N/A
Altman-Z -2.42
ROIC/WACCN/A
WACC5.17%
SOPH Yearly LT Debt VS Equity VS FCFSOPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • SOPH has a Current Ratio of 1.96. This is a normal value and indicates that SOPH is financially healthy and should not expect problems in meeting its short term obligations.
  • SOPH has a Current ratio of 1.96. This is comparable to the rest of the industry: SOPH outperforms 48.57% of its industry peers.
  • SOPH has a Quick Ratio of 1.84. This is a normal value and indicates that SOPH is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.84, SOPH perfoms like the industry average, outperforming 45.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.84
SOPH Yearly Current Assets VS Current LiabilitesSOPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SOPH Growth Analysis

3.1 Past

  • SOPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.89%.
  • Looking at the last year, SOPH shows a quite strong growth in Revenue. The Revenue has grown by 18.56% in the last year.
  • Measured over the past years, SOPH shows a very strong growth in Revenue. The Revenue has been growing by 22.16% on average per year.
EPS 1Y (TTM)-17.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
Revenue 1Y (TTM)18.56%
Revenue growth 3Y17.56%
Revenue growth 5Y22.16%
Sales Q2Q%22.41%

3.2 Future

  • Based on estimates for the next years, SOPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.16% on average per year.
  • SOPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.35% yearly.
EPS Next Y18.49%
EPS Next 2Y16.53%
EPS Next 3Y16.16%
EPS Next 5YN/A
Revenue Next Year23.18%
Revenue Next 2Y21.36%
Revenue Next 3Y22.34%
Revenue Next 5Y25.35%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SOPH Yearly Revenue VS EstimatesSOPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
SOPH Yearly EPS VS EstimatesSOPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. SOPH Valuation Analysis

4.1 Price/Earnings Ratio

  • SOPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SOPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SOPH Price Earnings VS Forward Price EarningsSOPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SOPH Per share dataSOPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SOPH's earnings are expected to grow with 16.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.53%
EPS Next 3Y16.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SOPH Dividend Analysis

5.1 Amount

  • SOPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SOPH Fundamentals: All Metrics, Ratios and Statistics

SOPHIA GENETICS SA

NASDAQ:SOPH (4/24/2026, 8:09:04 PM)

After market: 4.85 0 (0%)

4.85

-0.02 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-03
Earnings (Next)05-05
Inst Owners37.99%
Inst Owner Change-0.07%
Ins Owners6.67%
Ins Owner Change36.54%
Market Cap347.60M
Revenue(TTM)77.27M
Net Income(TTM)-79.00M
Analysts86
Price Target7.82 (61.24%)
Short Float %0.38%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.2%
Min EPS beat(2)-13.2%
Max EPS beat(2)-3.2%
EPS beat(4)0
Avg EPS beat(4)-15.01%
Min EPS beat(4)-40.66%
Max EPS beat(4)-2.99%
EPS beat(8)2
Avg EPS beat(8)-4.4%
EPS beat(12)4
Avg EPS beat(12)-2.91%
EPS beat(16)7
Avg EPS beat(16)3.07%
Revenue beat(2)2
Avg Revenue beat(2)4.48%
Min Revenue beat(2)3.68%
Max Revenue beat(2)5.27%
Revenue beat(4)4
Avg Revenue beat(4)3.67%
Min Revenue beat(4)2.77%
Max Revenue beat(4)5.27%
Revenue beat(8)4
Avg Revenue beat(8)-0.76%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)6
Avg Revenue beat(16)-0.97%
PT rev (1m)4.55%
PT rev (3m)4.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-269.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.5
P/FCF N/A
P/OCF N/A
P/B 7.37
P/tB 30.89
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS1.08
BVpS0.66
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -48.46%
ROE -167.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.4%
FCFM N/A
ROA(3y)-42.34%
ROA(5y)-37.18%
ROE(3y)-94.83%
ROE(5y)-70.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.85%
GM growth 5Y1.59%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.46%
Cap/Sales 11.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.84
Altman-Z -2.42
F-Score2
WACC5.17%
ROIC/WACCN/A
Cap/Depr(3y)98.75%
Cap/Depr(5y)133.47%
Cap/Sales(3y)12.83%
Cap/Sales(5y)15.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
EPS Next Y18.49%
EPS Next 2Y16.53%
EPS Next 3Y16.16%
EPS Next 5YN/A
Revenue 1Y (TTM)18.56%
Revenue growth 3Y17.56%
Revenue growth 5Y22.16%
Sales Q2Q%22.41%
Revenue Next Year23.18%
Revenue Next 2Y21.36%
Revenue Next 3Y22.34%
Revenue Next 5Y25.35%
EBIT growth 1Y-1.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.58%
EBIT Next 3Y23.53%
EBIT Next 5Y23.54%
FCF growth 1Y12.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.18%
OCF growth 3YN/A
OCF growth 5YN/A

SOPHIA GENETICS SA / SOPH Fundamental Analysis FAQ

What is the fundamental rating for SOPH stock?

ChartMill assigns a fundamental rating of 2 / 10 to SOPH.


Can you provide the valuation status for SOPHIA GENETICS SA?

ChartMill assigns a valuation rating of 0 / 10 to SOPHIA GENETICS SA (SOPH). This can be considered as Overvalued.


Can you provide the profitability details for SOPHIA GENETICS SA?

SOPHIA GENETICS SA (SOPH) has a profitability rating of 1 / 10.


How financially healthy is SOPHIA GENETICS SA?

The financial health rating of SOPHIA GENETICS SA (SOPH) is 1 / 10.